Evidence map›Paper›PMID 41426340›Full record

ArticleFrontiers in oncology2025

Eribulin and sintilimab combined with radiotherapy in a heavily pretreated patient with advanced retroperitoneal myxoid pleomorphic liposarcoma: a case report and literature review.

Hongyu Zhuo, Dongna Li, Yang Fu, Xinyao Zhang, Xin He, Ying Xu, Jie Liu, Yu Jiang, Yaotiao Deng

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hongyu Zhuo *Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Dongna Li *West China Clinical Medical College, Sichuan University, Chengdu, China.
Yang Fu *Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Xinyao ZhangDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Xin HeDepartment of pathology, West China Hospital, Sichuan University, Chengdu, China.
Ying XuWest China Clinical Medical College, Sichuan University, Chengdu, China.
Jie LiuDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Yu JiangDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Yaotiao DengDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myxoid pleomorphic liposarcoma (MPLPS) is an ultra-rare subtype of soft tissue sarcoma. The limited number of reported cases has led to significant challenges in its clinical management. Here, we present the case of a 52-year-old woman diagnosed with advanced retroperitoneal MPLPS. As first-line therapy, she underwent 4 cycles of chemotherapy with doxorubicin and ifosfamide. Anlotinib was subsequently added to the first-line regimen. Following this, she received gemcitabine plus albumin paclitaxel as second-line therapy. Notably, a partial response (PR) was achieved and sustained for 12 months following the administration of eribulin and sintilimab combined with radiotherapy. The demonstrated effectiveness of this multidisciplinary approach underscores its potential as a novel treatment strategy for patients with advanced MPLPS. To our knowledge, this article represents the first detailed documentation of multidisciplinary diagnosis and treatment of MPLPS.

Indexed as

eribulinmyxoid pleomorphic liposarcomapartial responsepathologyPD-1 inhibitor

Identifiers

PMID41426340
PMCPMC12714597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.